Status:
COMPLETED
A Pilot Trial of Acute N-Acetylcysteine Effects on Working Memory and Other Cognitive Functions in Schizophrenia
Lead Sponsor:
Yale University
Collaborating Sponsors:
National Alliance for Research on Schizophrenia and Depression
Conditions:
Schizophrenia
Eligibility:
All Genders
18-60 years
Phase:
NA
Brief Summary
The purpose of this study is to evaluate the effects of the amino acid supplement N-Acetylcysteine versus placebo on working memory and other cognitive functions in persons with a diagnosis of schizop...
Detailed Description
Working memory impairment in Schizophrenia is produced by deficiencies of feedback inhibition of glutamate release, due to low cysteine-glutamate antiporter activity. Because of this mechanism, we are...
Eligibility Criteria
Inclusion
- Subjects will be between 18-60
- Meet Diagnostic and Statistical Manual-IV (DSM) criteria for schizophrenia
- Be on a stable dose of antipsychotic medication for at least 1 month
- Be deemed clinically stable for 3 months by the regular clinical staff
Exclusion
- Current substance or alcohol abuse
- Pregnancy
- Clozapine treatment
- Known sensitivity to sulphur containing compounds
- Previous diagnosis of mental retardation
- Nitroglycerin use
- Asthma diagnosis, verified and treated by a primary care doctor
- Use of any other medication that may interact with the study medication
Key Trial Info
Start Date :
February 1 2010
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
November 1 2011
Estimated Enrollment :
28 Patients enrolled
Trial Details
Trial ID
NCT01232790
Start Date
February 1 2010
End Date
November 1 2011
Last Update
December 1 2015
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Connecticut Mental Health Center
New Haven, Connecticut, United States, 06519